Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents

On July 16, 2026, the Expert Council of the National Association of Pediatric Neurologists convened in Moscow in a hybrid format. The Council reviewed adjunctive pharmacotherapy for hyperkinetic disorders (F90 according to ICD-10; Attention-deficit hyperactivity disorders, ADHD; 6A05 according to ICD-11) in children and adolescents, focusing on evidence and clinical experience with medications used In Russian practice beyond the international first-line standard. Using the 2019 CECCMP evidence evaluation system and the current procedure for developing clinical guidelines linked to ICD-10 categories in the Russian Federation, the Council stratified medications into two groups. Group A, with the strongest evidence base (double-blind randomized controlled trial with a primary endpoint achieved in ADHD), includes Prospekta. Group B, with a limited evidence base, includes Cortexin, Tenoten for children, Cerebrolysin, Semax, Cogitum, Magne B6, Pantoham, and Mexidol. Adjunctive pharmacotherapy is recommended only as part of a multidisciplinary approach that includes psychoeducation and behavioral interventions. It is not a substitute for atomoxetine therapy for eligible patients.

Authors

Institutions

Publication Details

Journal
S S Korsakov Journal of Neurology and Psychiatry
Published
2026-10-22
DOI
https://doi.org/10.17116/jnevro2026126092126
Primary Topic
Attention Deficit Hyperactivity Disorder
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents

M. V. Shumilina, Комарова Ирина Борисовна, А. Н. Бархатова, A. V. Sulimov et al.
S S Korsakov Journal of Neurology and Psychiatry
Attention Deficit Hyperactivity Disorder
article

Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents

M. V. Shumilina, Комарова Ирина Борисовна, А. Н. Бархатова, A. V. Sulimov, А. V. Goryunov, Leonid Semenovich Chutko, Nikolay N. Zavadenko, Oleg L. Lapochkin, Зыков Валерий Петрович, Северин Вячеславович Гречаный, M. A. Yamin, Igor V. Makarov, Жужуна Мурмановна Цоцонава, A. V. Goryunova, Yu. E. Nesterovskiy, T.A. Kupriyanova, E.V. Koren
article en

Abstract

On July 16, 2026, the Expert Council of the National Association of Pediatric Neurologists convened in Moscow in a hybrid format. The Council reviewed adjunctive pharmacotherapy for hyperkinetic disorders (F90 according to ICD-10; Attention-deficit hyperactivity disorders, ADHD; 6A05 according to ICD-11) in children and adolescents, focusing on evidence and clinical experience with medications used In Russian practice beyond the international first-line standard. Using the 2019 CECCMP evidence evaluation system and the current procedure for developing clinical guidelines linked to ICD-10 categories in the Russian Federation, the Council stratified medications into two groups. Group A, with the strongest evidence base (double-blind randomized controlled trial with a primary endpoint achieved in ADHD), includes Prospekta. Group B, with a limited evidence base, includes Cortexin, Tenoten for children, Cerebrolysin, Semax, Cogitum, Magne B6, Pantoham, and Mexidol. Adjunctive pharmacotherapy is recommended only as part of a multidisciplinary approach that includes psychoeducation and behavioral interventions. It is not a substitute for atomoxetine therapy for eligible patients.

S S Korsakov Journal of Neurology and PsychiatryVol. 126(9)
St.Petersburg V.M.Bekhterev Psychoneurological Research Institute (RU), Pirogov Russian National Research Medical University (RU), Russian Medical Academy of Continuous Professional Education (RU), Astrakhan State Medical University (RU), Federal Medical Research Centre for Psychiatry and Narcology (RU), North-Western State Medical University named after I.I. Mechnikov (RU), Mental Health Research Center of Russian Academy of Medical Sciences (RU), Children's City Clinical Hospital No. 9 (RU), Saint Petersburg State Pediatric Medical University (RU)
Openalex Percentile: Top 13%
Attention Deficit Hyperactivity Disorder
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon